Skip to content

Study · Not a test of the peptide alone · 2025

11 results

Non-Arteritic Anterior Ischemic Optic Neuropathy in an Otherwise Healthy Young Adult Patient Treated with Liraglutide and Semaglutide for Weight Loss: A Cautionary Tale.

Lixi F, Calabresi V, Cukurova F, Giannaccare G

International medical case reports journal7 Aug 2025Cited by 8 (Europe PMC)

PMID40800673 (opens in a new tab)PMCIDPMC12339668 (opens in a new tab)DOI10.2147/imcrj.s531930 (opens in a new tab)PepBankPUB-40800673
Read at sourcePubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study11

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone11

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 01HumanNot a test of Liraglutide aloneCase report or seriesSafety outcome

    In one case with sequential liraglutide and semaglutide therapy for weight loss, progressive right-eye visual-acuity decline began one month after liraglutide initiation.

    In plain wordsIn one case with sequential liraglutide and semaglutide therapy, right-eye vision worsened one month after liraglutide began.

    Peptide
    Liraglutide
    Outcome
    Decreaseprogressive visual-acuity decline
    Study

    n = 1

    Outcome group
    Adverse events · Eye

    Source sentences

    Summary
    A 47-year-old Caucasian female with a Body Mass Index (BMI) of 27.92, and no known history of diabetes, hypertension, or ischemic heart disease, developed a progressive decline in visual acuity in the right eye one month after initiating liraglutide therapy for weight loss.
    1 context sentence
    Summary · context
    Liraglutide therapy was continued for further three months and then switched to semaglutide owing to poor clinical results.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 02HumanNot a test of Liraglutide aloneCase report or seriesSafety outcome

    In one case with sequential liraglutide and semaglutide therapy, initial ophthalmic examination found right-eye best-corrected visual acuity of 20/40.

    In plain wordsIn one case with sequential liraglutide and semaglutide therapy, initial right-eye vision measured 20/40.

    Peptide
    Liraglutide
    Outcome
    Not applicablebest-corrected visual acuity
    Study

    n = 1

    Outcome group
    Adverse events · Eye

    Source sentences

    Summary
    Upon symptom presentation, ophthalmic examination performed elsewhere revealed a best-corrected visual acuity (BCVA) of 20/40, optic nerve head (ONH) swelling, and inferior hemifield scotoma on Humphrey Visual Field testing.
    2 context sentences
    Summary · context
    A 47-year-old Caucasian female with a Body Mass Index (BMI) of 27.92, and no known history of diabetes, hypertension, or ischemic heart disease, developed a progressive decline in visual acuity in the right eye one month after initiating liraglutide therapy for weight loss.
    Summary · context
    Liraglutide therapy was continued for further three months and then switched to semaglutide owing to poor clinical results.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 03HumanNot a test of Liraglutide aloneCase report or seriesSafety outcome

    In one case with sequential liraglutide and semaglutide therapy, initial ophthalmic examination found optic nerve head swelling.

    In plain wordsIn one case with sequential liraglutide and semaglutide therapy, initial examination found optic-nerve swelling.

    Peptide
    Liraglutide
    Outcome
    Not applicableoptic nerve head swelling
    Study

    n = 1

    Outcome group
    Adverse events · Eye

    Source sentences

    Summary
    Upon symptom presentation, ophthalmic examination performed elsewhere revealed a best-corrected visual acuity (BCVA) of 20/40, optic nerve head (ONH) swelling, and inferior hemifield scotoma on Humphrey Visual Field testing.
    2 context sentences
    Summary · context
    A 47-year-old Caucasian female with a Body Mass Index (BMI) of 27.92, and no known history of diabetes, hypertension, or ischemic heart disease, developed a progressive decline in visual acuity in the right eye one month after initiating liraglutide therapy for weight loss.
    Summary · context
    Liraglutide therapy was continued for further three months and then switched to semaglutide owing to poor clinical results.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  4. 04HumanNot a test of Liraglutide aloneCase report or seriesSafety outcome

    In one case with sequential liraglutide and semaglutide therapy, initial visual-field testing found an inferior hemifield scotoma.

    In plain wordsIn one case with sequential liraglutide and semaglutide therapy, initial field testing found a lower-half visual-field blind spot.

    Peptide
    Liraglutide
    Outcome
    Not applicableinferior hemifield scotoma
    Study

    n = 1

    Outcome group
    Adverse events · Eye

    Source sentences

    Summary
    Upon symptom presentation, ophthalmic examination performed elsewhere revealed a best-corrected visual acuity (BCVA) of 20/40, optic nerve head (ONH) swelling, and inferior hemifield scotoma on Humphrey Visual Field testing.
    2 context sentences
    Summary · context
    A 47-year-old Caucasian female with a Body Mass Index (BMI) of 27.92, and no known history of diabetes, hypertension, or ischemic heart disease, developed a progressive decline in visual acuity in the right eye one month after initiating liraglutide therapy for weight loss.
    Summary · context
    Liraglutide therapy was continued for further three months and then switched to semaglutide owing to poor clinical results.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  5. 05HumanNot a test of Semaglutide aloneCase report or seriesSafety outcome

    In one case with sequential liraglutide and semaglutide therapy, later examination found right-eye best-corrected visual acuity limited to 20/400.

    In plain wordsIn one case with sequential liraglutide and semaglutide therapy, later right-eye vision was limited to 20/400.

    Peptide
    Semaglutide
    Outcome
    Not applicablebest-corrected visual acuity
    Study

    n = 1

    Outcome group
    Adverse events · Eye

    Source sentences

    Summary
    Upon examination, BCVA was limited to 20/400, ONH edema was evident and confirmed on optical coherence tomography (OCT), and further worsening of the visual field defects was detected.
    3 context sentences
    Summary · context
    A 47-year-old Caucasian female with a Body Mass Index (BMI) of 27.92, and no known history of diabetes, hypertension, or ischemic heart disease, developed a progressive decline in visual acuity in the right eye one month after initiating liraglutide therapy for weight loss.
    Summary · context
    Liraglutide therapy was continued for further three months and then switched to semaglutide owing to poor clinical results.
    Summary · context
    Eight months later, the patient discontinued weight loss therapy because of progressive visual deterioration and presented to our clinic for a second opinion.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  6. 06HumanNot a test of Semaglutide aloneCase report or seriesSafety outcome

    In one case with sequential liraglutide and semaglutide therapy, later examination found optic nerve head edema confirmed by optical coherence tomography.

    In plain wordsIn one case with sequential liraglutide and semaglutide therapy, later examination confirmed optic-nerve swelling by an eye scan.

    Peptide
    Semaglutide
    Outcome
    Not applicableoptic nerve head edema
    Study

    n = 1

    Outcome group
    Adverse events · Eye

    Source sentences

    Summary
    Upon examination, BCVA was limited to 20/400, ONH edema was evident and confirmed on optical coherence tomography (OCT), and further worsening of the visual field defects was detected.
    3 context sentences
    Summary · context
    A 47-year-old Caucasian female with a Body Mass Index (BMI) of 27.92, and no known history of diabetes, hypertension, or ischemic heart disease, developed a progressive decline in visual acuity in the right eye one month after initiating liraglutide therapy for weight loss.
    Summary · context
    Liraglutide therapy was continued for further three months and then switched to semaglutide owing to poor clinical results.
    Summary · context
    Eight months later, the patient discontinued weight loss therapy because of progressive visual deterioration and presented to our clinic for a second opinion.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  7. 07HumanNot a test of Semaglutide aloneCase report or seriesSafety outcome

    In one case with sequential liraglutide and semaglutide therapy, later examination detected further worsening of visual-field defects.

    In plain wordsIn one case with sequential liraglutide and semaglutide therapy, later field defects worsened further.

    Peptide
    Semaglutide
    Outcome
    Increasevisual-field defect worsening
    Study

    n = 1

    Outcome group
    Adverse events · Eye

    Source sentences

    Summary
    Upon examination, BCVA was limited to 20/400, ONH edema was evident and confirmed on optical coherence tomography (OCT), and further worsening of the visual field defects was detected.
    3 context sentences
    Summary · context
    A 47-year-old Caucasian female with a Body Mass Index (BMI) of 27.92, and no known history of diabetes, hypertension, or ischemic heart disease, developed a progressive decline in visual acuity in the right eye one month after initiating liraglutide therapy for weight loss.
    Summary · context
    Liraglutide therapy was continued for further three months and then switched to semaglutide owing to poor clinical results.
    Summary · context
    Eight months later, the patient discontinued weight loss therapy because of progressive visual deterioration and presented to our clinic for a second opinion.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  8. 08HumanNot a test of Semaglutide aloneCase report or seriesSafety outcome

    In one case with sequential liraglutide and semaglutide therapy, non-arteritic anterior ischemic optic neuropathy secondary to GLP-1 receptor agonists was diagnosed.

    In plain wordsIn one case with sequential liraglutide and semaglutide therapy, an optic-nerve disorder attributed to GLP-1 drugs was diagnosed.

    Peptide
    Semaglutide
    Outcome
    Not applicablenon-arteritic anterior ischemic optic neuropathy diagnosis
    Study

    n = 1

    Outcome group
    Adverse events · Eye

    Source sentences

    Summary
    Given the absence of anatomical and/or systemic risk factors, NAION secondary to GLP-1 RAs was diagnosed.
    3 context sentences
    Summary · context
    A 47-year-old Caucasian female with a Body Mass Index (BMI) of 27.92, and no known history of diabetes, hypertension, or ischemic heart disease, developed a progressive decline in visual acuity in the right eye one month after initiating liraglutide therapy for weight loss.
    Summary · context
    Liraglutide therapy was continued for further three months and then switched to semaglutide owing to poor clinical results.
    Summary · context
    Eight months later, the patient discontinued weight loss therapy because of progressive visual deterioration and presented to our clinic for a second opinion.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  9. 09HumanNot a test of Liraglutide aloneCase report or seriesSafety outcome

    In one woman after sequential liraglutide then semaglutide weight-loss therapy, NAION secondary to GLP-1 receptor agonists was diagnosed; no drug-isolated causal finding was established.

    In plain wordsIn one woman after liraglutide then semaglutide, an optic-nerve disorder attributed to GLP-1 drugs was diagnosed; individual drug causation was unproven.

    Peptide
    Liraglutide
    Outcome
    Not applicableNon-arteritic anterior ischemic optic neuropathy diagnosis
    Study

    n = 1

    Outcome group
    Adverse events · Eye

    Source sentences

    Summary
    Given the absence of anatomical and/or systemic risk factors, NAION secondary to GLP-1 RAs was diagnosed.
    3 context sentences
    Summary · context
    A 47-year-old Caucasian female with a Body Mass Index (BMI) of 27.92, and no known history of diabetes, hypertension, or ischemic heart disease, developed a progressive decline in visual acuity in the right eye one month after initiating liraglutide therapy for weight loss.
    Summary · context
    Liraglutide therapy was continued for further three months and then switched to semaglutide owing to poor clinical results.
    Summary · context
    Eight months later, the patient discontinued weight loss therapy because of progressive visual deterioration and presented to our clinic for a second opinion.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  10. 10HumanNot a test of Liraglutide aloneCase report or seriesSafety outcome

    In one woman receiving liraglutide then semaglutide for weight loss, therapy was discontinued eight months after the switch because of progressive visual deterioration; no isolated drug cause was established.

    In plain wordsIn one woman receiving liraglutide then semaglutide, weight-loss therapy stopped eight months after switching because vision progressively worsened; individual drug causation was unproven.

    Peptide
    Liraglutide
    Outcome
    Not applicableWeight-loss treatment discontinuation following visual deterioration
    Study

    n = 1

    Outcome group
    Adverse events · Eye

    Source sentences

    Summary
    Eight months later, the patient discontinued weight loss therapy because of progressive visual deterioration and presented to our clinic for a second opinion.
    2 context sentences
    Summary · context
    Liraglutide therapy was continued for further three months and then switched to semaglutide owing to poor clinical results.
    Summary · context
    A 47-year-old Caucasian female with a Body Mass Index (BMI) of 27.92, and no known history of diabetes, hypertension, or ischemic heart disease, developed a progressive decline in visual acuity in the right eye one month after initiating liraglutide therapy for weight loss.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  11. 11HumanNot a test of Semaglutide aloneCase report or seriesSafety outcome

    In one woman receiving liraglutide then semaglutide for weight loss, therapy was discontinued eight months after the switch because of progressive visual deterioration; no isolated drug cause was established.

    In plain wordsIn one woman receiving liraglutide then semaglutide, weight-loss therapy stopped eight months after switching because vision progressively worsened; individual drug causation was unproven.

    Peptide
    Semaglutide
    Outcome
    Not applicableWeight-loss treatment discontinuation following visual deterioration
    Study

    n = 1

    Outcome group
    Adverse events · Eye

    Source sentences

    Summary
    Eight months later, the patient discontinued weight loss therapy because of progressive visual deterioration and presented to our clinic for a second opinion.
    2 context sentences
    Summary · context
    Liraglutide therapy was continued for further three months and then switched to semaglutide owing to poor clinical results.
    Summary · context
    A 47-year-old Caucasian female with a Body Mass Index (BMI) of 27.92, and no known history of diabetes, hypertension, or ischemic heart disease, developed a progressive decline in visual acuity in the right eye one month after initiating liraglutide therapy for weight loss.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:06 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.